These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 25082276)

  • 21. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer.
    Eder JP; Vande Woude GF; Boerner SA; LoRusso PM
    Clin Cancer Res; 2009 Apr; 15(7):2207-14. PubMed ID: 19318488
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Status quo of research on HGFc-Met signaling pathway in cancers].
    Su HL; Liu FL; Hao T
    Zhonghua Zhong Liu Za Zhi; 2013 May; 35(5):321-4. PubMed ID: 24054005
    [No Abstract]   [Full Text] [Related]  

  • 23. 2,4-Diaminopyrimidine inhibitors of c-Met kinase bearing benzoxazepine anilines.
    Zificsak CA; Theroff JP; Aimone LD; Albom MS; Angeles TS; Brown RA; Galinis D; Grobelny JV; Herbertz T; Husten J; Kocsis LS; LoSardo C; Miknyoczki SJ; Murthy S; Rolon-Steele D; Underiner TL; Wells-Knecht KJ; Worrell CS; Zeigler KS; Dorsey BD
    Bioorg Med Chem Lett; 2011 Jan; 21(2):660-3. PubMed ID: 21190849
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of c-MET pathway inhibitors.
    Liu X; Newton RC; Scherle PA
    Expert Opin Investig Drugs; 2011 Sep; 20(9):1225-41. PubMed ID: 21740293
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Small molecule c-Met kinase inhibitors: a review of recent patents.
    Porter J
    Expert Opin Ther Pat; 2010 Feb; 20(2):159-77. PubMed ID: 20100000
    [TBL] [Abstract][Full Text] [Related]  

  • 26. O-linked triazolotriazines: potent and selective c-Met inhibitors.
    Chen F; Wang Y; Ai J; Zhan Z; Lv Y; Liang Z; Luo C; Mei D; Geng M; Duan W
    ChemMedChem; 2012 Jul; 7(7):1276-85. PubMed ID: 22539497
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A selective small molecule c-MET Inhibitor, PHA665752, cooperates with rapamycin.
    Ma PC; Schaefer E; Christensen JG; Salgia R
    Clin Cancer Res; 2005 Mar; 11(6):2312-9. PubMed ID: 15788682
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting receptor tyrosine kinase MET in cancer: small molecule inhibitors and clinical progress.
    Cui JJ
    J Med Chem; 2014 Jun; 57(11):4427-53. PubMed ID: 24320965
    [TBL] [Abstract][Full Text] [Related]  

  • 29. EGFR-TKI resistant non-small cell lung cancer (NSCLC): new developments and implications for future treatment.
    Brugger W; Thomas M
    Lung Cancer; 2012 Jul; 77(1):2-8. PubMed ID: 22281074
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discovery of a novel and potent series of thieno[3,2-b]pyridine-based inhibitors of c-Met and VEGFR2 tyrosine kinases.
    Claridge S; Raeppel F; Granger MC; Bernstein N; Saavedra O; Zhan L; Llewellyn D; Wahhab A; Deziel R; Rahil J; Beaulieu N; Nguyen H; Dupont I; Barsalou A; Beaulieu C; Chute I; Gravel S; Robert MF; Lefebvre S; Dubay M; Pascal R; Gillespie J; Jin Z; Wang J; Besterman JM; MacLeod AR; Vaisburg A
    Bioorg Med Chem Lett; 2008 May; 18(9):2793-8. PubMed ID: 18434145
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The emerging role of MET/HGF inhibitors in oncology.
    Scagliotti GV; Novello S; von Pawel J
    Cancer Treat Rev; 2013 Nov; 39(7):793-801. PubMed ID: 23453860
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design, synthesis and molecular docking studies of some novel spiro[indoline-3, 4'-piperidine]-2-ones as potential c-Met inhibitors.
    Ye L; Tian Y; Li Z; Jin H; Zhu Z; Wan S; Zhang J; Yu P; Zhang J; Wu S
    Eur J Med Chem; 2012 Apr; 50():370-5. PubMed ID: 22381355
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthesis and structure-activity relationship of aminopyridines with substituted benzoxazoles as c-Met kinase inhibitors.
    Lee J; Han SY; Jung H; Yang J; Choi JW; Chae CH; Park CH; Choi SU; Lee K; Ha JD; Lee CO; Ryu JW; Kim HR; Koh JS; Cho SY
    Bioorg Med Chem Lett; 2012 Jun; 22(12):4044-8. PubMed ID: 22579487
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discovery of a novel B-Raf fusion protein related to c-Met drug resistance.
    Dillon R; Nilsson CL; Shi SD; Lee NV; Krastins B; Greig MJ
    J Proteome Res; 2011 Nov; 10(11):5084-94. PubMed ID: 21936566
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synthesis and biological evaluation of 2-amino-5-aryl-3-benzylthiopyridine scaffold based potent c-Met inhibitors.
    Zhang D; Zhang X; Ai J; Zhai Y; Liang Z; Wang Y; Chen Y; Li C; Zhao F; Jiang H; Geng M; Luo C; Liu H
    Bioorg Med Chem; 2013 Nov; 21(21):6804-20. PubMed ID: 23993328
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design, synthesis and structure-activity relationships of novel biarylamine-based Met kinase inhibitors.
    Williams DK; Chen XT; Tarby C; Kaltenbach R; Cai ZW; Tokarski JS; An Y; Sack JS; Wautlet B; Gullo-Brown J; Henley BJ; Jeyaseelan R; Kellar K; Manne V; Trainor GL; Lombardo LJ; Fargnoli J; Borzilleri RM
    Bioorg Med Chem Lett; 2010 May; 20(9):2998-3002. PubMed ID: 20382527
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The combination of multiple receptor tyrosine kinase inhibitor and mammalian target of rapamycin inhibitor overcomes erlotinib resistance in lung cancer cell lines through c-Met inhibition.
    Nakachi I; Naoki K; Soejima K; Kawada I; Watanabe H; Yasuda H; Nakayama S; Yoda S; Satomi R; Ikemura S; Terai H; Sato T; Ishizaka A
    Mol Cancer Res; 2010 Aug; 8(8):1142-51. PubMed ID: 20647329
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The discovery of benzanilides as c-Met receptor tyrosine kinase inhibitors by a directed screening approach.
    Allen JV; Bardelle C; Blades K; Buttar D; Chapman L; Colclough N; Dossetter AG; Garner AP; Girdwood A; Lambert C; Leach AG; Law B; Major J; Plant H; Slater AM
    Bioorg Med Chem Lett; 2011 Sep; 21(18):5224-9. PubMed ID: 21835616
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor.
    Pan BS; Chan GK; Chenard M; Chi A; Davis LJ; Deshmukh SV; Gibbs JB; Gil S; Hang G; Hatch H; Jewell JP; Kariv I; Katz JD; Kunii K; Lu W; Lutterbach BA; Paweletz CP; Qu X; Reilly JF; Szewczak AA; Zeng Q; Kohl NE; Dinsmore CJ
    Cancer Res; 2010 Feb; 70(4):1524-33. PubMed ID: 20145145
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genentech to salvage anti-MET antibody with subgroup analysis.
    Sheridan C
    Nat Biotechnol; 2014 May; 32(5):399-400. PubMed ID: 24811494
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.